Abstract
A recombinant vaccinia virus termed pLC201VV was designed to coexpress the L1 and L2 late genes of human papillomavirus type 16 (HPV16). Synthesis of the L1 and L2 proteins occurred in cells infected with pLC201VV, and 40-nm virus-like particles with a density of 1.31 g/ml were produced in the nuclei of cells synthesizing both L1 and L2, but not in cells synthesizing either protein alone. Virus-like particles were partially purified from infected cells by sucrose gradient sedimentation and shown to consist of capsomeres similar to HPV and contain glycosylated L1 viral capsid protein. The production of HPV-like particles using recombinant vaccinia virus should be useful for biochemical studies and could provide a safe source of material for the development of a vaccine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Base Sequence
-
Capsid Proteins*
-
Cell Line
-
Genes, Viral*
-
Glycosylation
-
Humans
-
Microscopy, Electron
-
Molecular Sequence Data
-
Molecular Weight
-
Oligodeoxyribonucleotides
-
Oncogene Proteins, Viral / genetics*
-
Oncogene Proteins, Viral / immunology
-
Oncogene Proteins, Viral / isolation & purification
-
Open Reading Frames*
-
Papillomaviridae / genetics*
-
Papillomaviridae / physiology
-
Papillomaviridae / ultrastructure
-
Polymerase Chain Reaction
-
Promoter Regions, Genetic
-
Recombination, Genetic
-
Vaccinia virus / genetics*
-
Virion / genetics*
-
Virion / physiology
Substances
-
Capsid Proteins
-
L2 protein, Human papillomavirus type 16
-
Oligodeoxyribonucleotides
-
Oncogene Proteins, Viral
-
L1 protein, Human papillomavirus type 16